Deciphering oncogenic drivers: From single genes to integrated pathways

Briefings in Bioinformatics

Volumn 16, Issue 3, 2014, Pages 413-428

  Chen, Jiajia ^a,b   Sun, Maomin ^a   Shen, Bairong ^a  

^a SOOCHOW UNIVERSITY   (China)

^b SUZHOU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cancer driver; Mutation; Network; Pathway

Indexed keywords

DNA;

ALGORITHM; ANIMAL; AUTOMATED PATTERN RECOGNITION; CARCINOGENESIS; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; GENETICS; HUMAN; MACHINE LEARNING; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE; PROCEDURES; SIGNAL TRANSDUCTION;

ALGORITHMS; ANIMALS; BASE SEQUENCE; CARCINOGENESIS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; MACHINE LEARNING; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENES; PATTERN RECOGNITION, AUTOMATED; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 84929736259     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbu039     Document Type: Article

References (85)

1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
2. Network TCGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
3. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467-72.
4. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
5. (TCGA) TCGARN. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
6. Mardis ER. A decade's perspective on DNA sequencing technology. Nature 2011;470:198-203.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
8. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
11. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899-905.
12. Overdevest JB, Theodorescu D, Lee JK. Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem 2009;55:684-97.
13. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008;452:553-63.
14. Gonzalez-Perez A, Mustonen V, Reva B, et al. Computational approaches to identify functional genetic variants in cancer genomes. NatMethods 2013;10:723-9.
15. Raphael BJ, Dobson JR, Oesper L, et al. Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med 2014;6:5.
16. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. NatMed 2004;10:789-99.
17. Frohling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007;12:501-13.
18. Torkamani A, Schork NJ. Prediction of cancer driver mutations in protein kinases. Cancer Res 2008;68:1675-82.
19. Carter H, Samayoa J, Hruban RH, et al. Prioritization of driver mutations in pancreatic cancer using cancerspecific high-throughput annotation of somatic mutations (CHASM). Cancer BiolTher 2010;10:582-7.
20. Tan H, Bao J, Zhou X. A novel missense-mutation-related feature extraction scheme for 'driver' mutation identification. Bioinformatics 2012;28:2948-55.
21. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
22. Hu J, Ng PC. Predicting the effects of frameshifting indels. Genome Biol 2012;13:R9.
23. Hu J, Ng PC. SIFT Indel: predictions for the functional effects of amino acid insertions/deletions in proteins. PLoS One 2013;8:e77940.
24. Zhao H, Yang Y, Lin H, et al. DDIG-in: discriminating between disease-associated and neutral non-frameshifting micro-indels. Genome Biol 2013;14:R23.
25. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001;11:863-74.
26. Kaminker JS, Zhang Y, Watanabe C, et al. CanPredict: a computational tool for predicting cancer-associated missense mutations. Nucleic Acids Res 2007;35:W595-8.
27. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011;39:e118.
28. Gonzalez-Perez A, Deu-Pons J, Lopez-Bigas N. Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. GenomeMed 2012;4:89.
29. Ryslik GA, Cheng Y, Cheung KH, et al. Utilizing protein structure to identify non-random somatic mutations. BMC Bioinformatics 2013;14:190.
30. Choi Y, Sims GE, Murphy S, et al. Predicting the functional effect of amino acid substitutions and indels. PLoS One 2012;7:e46688.
31. Carter H, Chen S, Isik L, et al. Cancer-specific highthroughput annotation of somatic mutations: computational prediction of driver missense mutations. CancerRes 2009;69:6660-7.
32. Kaminker JS, Zhang Y, Waugh A, et al. Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res 2007;67:465-73.
33. Clifford RJ, Edmonson MN, Nguyen C, et al. Large-scale analysis of non-synonymous coding region single nucleotide polymorphisms. Bioinformatics 2004;20:1006-14.
34. Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007;104:20007-12.
35. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
36. Parmigiani G, Boca SM. CancerMutationAnalysis: Cancer mutation analysis. Bioconductor 2004. R package version 1.10.0.
37. Dees ND, Zhang Q, Kandoth C, et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res 2012;22:1589-98.
38. Mermel CH, Schumacher SE, Hill B, et al. GISTIC2 0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011;12:R41.
39. Sanchez-Garcia F, Akavia UD, Mozes E, et al. JISTIC:identification of significant targets in cancer. BMC Bioinformatics 2010;11:189.
40. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013;499:214-18.
41. Reimand J, Bader GD. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol 2013;9:637.
42. Chen CL, Rappailles A, Duquenne L, et al. Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. GenomeRes 2010;20:447-57.
43. Baudot A, Real FX, Izarzugaza JM, et al. From cancer genomes to cancer models: bridging the gaps. EMBORep 2009;10:359-66.
44. Greenman C, Wooster R, Futreal PA, et al. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 2006;173:2187-98.
45. Akavia UD, Litvin O, Kim J, et al. An integrated approach to uncover drivers of cancer. Cell 2010;143:1005-17.
46. Tran LM, Zhang B, Zhang Z, et al. Inferring causal genomic alterations in breast cancer using gene expression data. BMC Syst Biol 2011;5:121.
47. Masica DL, Karchin R. Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res 2011;71:4550-61.
48. Leary RJ, Lin JC, Cummins J, et al. Integrated analysis of homozygous deletions, focal amplifications, sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA 2008;105:16224-9.
49. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
50. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
51. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basallike breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
52. Tao Y, Ruan J, Yeh SH, et al. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. ProcNatl Acad SciUSA 2011;108:12042-7.
53. Russnes HG, Navin N, Hicks J, et al. Insight into the heterogeneity of breast cancer through next-generation sequencing. JClin Invest 2011;121:3810-18.
54. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. NEnglJMed 2012;366:883-92.
55. Tang Y, Yan W, Chen J, et al. Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer. BMCSyst Biol 2013;7:S6.
56. Jiang J, Cui W, Vongsangnak W, et al. Post genome-wide association studies functional characterization of prostate cancer risk loci. BMCGenomics 2013;14:S9.
57. Hu Y, Li J, Yan W, et al. Identifying novel glioma associated pathways based on systems biology level meta-analysis. BMCSyst Biol 2013;7:S9.
58. Yeang CH, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEBJ 2008;22:2605-22.
59. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis:current approaches and outstanding challenges. PLoS Comput Biol 2012;8:e1002375.
60. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
61. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000;28:27-30.
62. Joshi-Tope G, Gillespie M, Vastrik I, et al. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 2005;33:D428-32.
63. Nishimura D. BioCarta. Biotech Softw Internet Rep 2001;2:117-20.
64. Schaefer CF, Anthony K, Krupa S, et al. PID: the pathway interaction database. Nucleic Acids Res 2009;37:D674-9.
65. Wendl MC, Wallis JW, Lin L, et al. PathScan: a tool for discerning mutational significance in groups of putative cancer genes. Bioinformatics 2011;27:1595-602.
66. Vaske CJ, Benz SC, Sanborn JZ, et al. Inference of patientspecific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010;26:i237-45.
67. Vandin F, Upfal E, Raphael BJ. Denovo discovery of mutated driver pathways in cancer. GenomeRes 2012;22:375-85.
68. Miller CA, Settle SH, Sulman EP, et al. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. BMCMedGenomics 2011;4:34.
69. Leiserson MD, Blokh D, Sharan R, et al. Simultaneous identification of multiple driver pathways in cancer. PLoS Comput Biol 2013;9:e1003054.
70. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. NatMed 2004;10:789-99.
71. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
72. Mao JH, To MD, Perez-Losada J, et al. Mutually exclusive mutations of the Pten and RAS pathways in skin tumor progression. Genes Dev 2004;18:1800-5.
73. Zhao J, Zhang S, Wu LY, et al. Efficient methods for identifying mutated driver pathways in cancer. Bioinformatics 2012;28:2940-7.
74. McCormick F. Signalling networks that cause cancer. Trends Cell Biol 1999;9:M53-6.
75. Cerami E, Demir E, Schultz N, et al. Automated network analysis identifies core pathways in glioblastoma. PLoS One 2010;5:e8918.
76. Ciriello G, Cerami E, Sander C, et al. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 2012;22:398-406.
77. Glaab E, Baudot A, Krasnogor N, et al. EnrichNet: network- based gene set enrichment analysis. Bioinformatics 2012;28:i451-7.
78. Vandin F, Upfal E, Raphael BJ. Algorithms for detecting significantly mutated pathways in cancer. J Comput Biol 2011;18:507-22.
79. Paull EO, Carlin DE, Niepel M, et al. Discovering causal pathways linking genomic events to transcriptional states using Tied Diffusion Through Interacting Events (TieDIE). Bioinformatics 2013;29:2757-64.
80. Torkamani A, Schork NJ. Identification of rare cancer driver mutations by network reconstruction. Genome Res 2009;19:1570-8.
81. Cooper DN, Krawczak M, Polychronakos C, et al. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum Genet 2013;132:1077-30.
82. Amberger J, Bocchini CA, Scott AF, et al. McKusick's online Mendelian inheritance in man (OMIM). Nucleic Acids Res 2009;37:D793-6.
83. Mottaz A, David FP, Veuthey AL, et al. Easy retrieval of single amino-acid polymorphisms and phenotype information using SwissVar. Bioinformatics 2010;26:851-2.
84. Landrum MJ, Lee JM, Riley GR, et al. ClinVar:public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2013;42:D980-5.
85. Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database: 2008 update. GenomeMed 2009;1:13.